Capmatinib

Generic name: Capmatinib
Brand names: Tabrecta
Dosage form: oral tablet (150 mg; 200 mg)
Drug class: Multikinase inhibitors

Usage of Capmatinib

Capmatinib is used to treat non-small cell lung cancer that has spread to other parts of the body (metastatic) or cannot be removed with surgery.

Capmatinib is used only if your cancer has a specific genetic marker (an abnormal "MET" gene). Your doctor will test you for this gene.

Capmatinib may also be used for purposes not listed in this medication guide.

Capmatinib side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Capmatinib may cause serious side effects. Call your doctor at once if you have:

new or worsening cough, chest pain, trouble breathing;

fever, cough with mucus;

severe ongoing nausea and vomiting; or

signs of liver or pancreas problems--loss of appetite, upper stomach pain (that may spread to your back), nausea or vomiting, fast heart rate, dark urine, jaundice (yellowing of the skin or eyes).

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects of capmatinib may include:

trouble breathing;

nausea, vomiting, decreased appetite;

feeling weak or tired;

abnormal liver function tests; or

swelling in your hands or feet.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Capmatinib

Tell your doctor if you have ever had:

lung problems other than lung cancer; or

liver disease.

You may need to have a negative pregnancy test before starting this treatment.

Both men and women using capmatinib should use effective birth control to prevent pregnancy. Capmatinib can harm an unborn baby if the mother or father is using this medicine.

Keep using birth control for at least 1 week after your last dose. Tell your doctor right away if a pregnancy occurs while either the mother or the father is using capmatinib.

Do not breastfeed while using this medicine, and for at least 1 week after your last dose.

Relate drugs

How to use Capmatinib

Usual Adult Dose for Non-Small Cell Lung Cancer:

400 mg orally 2 times daily Use: For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an approved test

Warnings

Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

What other drugs will affect Capmatinib

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Other drugs may affect capmatinib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Popular FAQ

Tabrecta starts working immediately to slow your cancer growth but if you are someone who responds to Tabrecta, it may take a few weeks before your tumors become noticeably smaller or stop growing. 68% of people taking Tabrecta as their first treatment achieved a response.

In clinical studies, the overall response rate (ORR) for Tebrecta in 60 participants who had never received any treatment for non-small cell lung cancer (NSCLC) was 68%, with half of patients having a duration of response lasting 16.6 months. Continue reading

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.